{rfName}
So

Indexed in

License and use

Citations

8

Altmetrics

Analysis of institutional authors

Carcereny, EAuthor

Share

November 21, 2024
Publications
>
Article
No

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC

Publicated to:European Journal Of Cancer. 208 114204- - 2024-09-01 208(), DOI: 10.1016/j.ejca.2024.114204

Authors: Hochmair, MJ; Vermaelen, K; Mountzios, G; Carcereny, E; Dooms, C; Lee, SH; Morocz, E; Kato, T; Ciuleanu, TE; Dy, GK; Parente, B; O'Byrne, KJ; Chu, QS; De Castro, G Jr; Girard, N; Snyder, W; Tran, Q; Kormany, W; Houk, B; Mehta, B; Curioni-Fontecedro, A

Affiliations

- Author
Amgen Inc - Author
Catalan Inst Oncol Badalona, Med Oncol Dept, Badalona Appl Res Grp Oncol - Author
Ghent Univ Hosp, Dept Pulm Med - Author
Henry Dunant Hosp Ctr, Clin Trials Unit - Author
Hosp CUF Porto, Pulmonol Dept - Author
Hosp Fribourg - Author
Kanagawa Canc Ctr, Dept Thorac Oncol - Author
Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunnerstr 68 - Author
Pulmonol Hosp - Author
Queensland Univ Technol, Brisbane - Author
Roswell Pk Comprehens Canc Ctr - Author
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med - Author
Univ Alberta, Cross Canc Inst, Dept Oncol, Div Med Oncol, Edmonton - Author
Univ Hosp KU Leuven, Dept Resp Dis - Author
Univ Med & Pharm Iuliu Hatieganu - Author
UVSQ, Paris Saclay - Author
See more

Abstract

Background: Sotorasib 960 mg once daily is approved to treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib exhibits non-dose proportional pharmacokinetics and clinical responses at lower doses; therefore, we evaluated the efficacy and safety of sotorasib 960 mg and 240 mg. Methods: In this phase 2, randomized, open-label study, adults with KRAS G12C-mutated advanced NSCLC received sotorasib 960 mg or 240 mg once daily. Primary endpoints were objective response rate (ORR) and safety. Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and pharmacokinetics. The study was not powered for formal statistical hypothesis testing. Results: In the 960 mg group (n = 104), ORR was 32.7 % and DCR was 86.5 %. In the 240 mg group (n = 105), ORR was 24.8 % and DCR was 81.9 %. Median PFS was 5.4 months (960 mg) and 5.6 months (240 mg). At a median follow-up of 17.5 months, median OS was 13.0 months (960 mg) and 11.7 months (240 mg). AUC0-24 h and Cmax were 1.3-fold numerically higher with the 960 mg dose. Treatment-emergent adverse events (TEAEs, >= 10 %) for 960 mg and 240 mg doses, respectively, were diarrhea (39.4 %; 31.7 %), nausea (23.1 %; 19.2 %), increased alanine aminotransaminase (14.4 %; 17.3 %), and increased aspartate aminotransferase (13.5 %; 13.5 %). Conclusions: Patients treated with sotorasib 960 mg once daily had numerically higher ORR and DCR, and longer DOR and OS, than patients treated with 240 mg in this descriptive analysis. TEAEs were manageable with label- directed dose modifications. Clinical trial registration: NCT03600883

Keywords

AdultAdvanced cancerAgedAged, 80 and overAlanine aminotransferaseAntineoplastic metal complexArea under the curveArticleAspartate aminotransferaseBiological therapyCancer chemotherapyCancer combination chemotherapyCancer controlCarboplatinCarcinoma, non-small-cell lungClinical trialControlled studyDecreased appetiteDiarrheaDose comparisonDrug administrationDrug administration scheduleDrug dose reductionDrug efficacyDrug safetyDrug therapyDrug withdrawalEcog performance statusFatigueFemaleFollow upGastrointestinal toxicityGene mutationGeneticsHumanHumansHypertransaminasemiaK ras proteinKras protein, humanLung neoplasmsLung tumorMajor clinical studyMaleMaximum concentrationMiddle agedMulticenter studyMutationNauseaNon small cell lung cancerOpen studyOverall survivalPathologyPatient history of therapyPembrolizumabPemetrexedPharmacokineticsPhase 2 clinical trialPiperazine derivativePiperazinesPneumoniaProgression free survivalProgression-free survivalProtein p21Proto-oncogene proteins p21(ras)Pyridine derivativePyridinesPyrimidine derivativePyrimidinesRandomized controlled trialSotorasibTreatment responseTreatment response timeVasculotropin inhibitorVery elderlyVomiting

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal European Journal Of Cancer due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 45/326, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-08-09:

  • WoS: 1
  • Scopus: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-09:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 5.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 5 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 20.95.
  • The number of mentions on the social network X (formerly Twitter): 6 (Altmetric).
  • The number of mentions in news outlets: 2 (Altmetric).

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Australia; Austria; Belgium; Brazil; Canada; France; Greece; Hungary; Japan; Oman; Portugal; Republic of Korea; Switzerland; United States of America.